About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Austin | 15,205 Studies Near You | Clareo Health

Clinical Trials LocationsAustin

Clinical Trials in Austin

Discover 15,205 clinical trials near Austin, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11461-11480 of 15,205 trials

COMPLETEDPhase 3< 1 mile

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00099229

This purpose of this study is to evaluate the safety and efficacy of Licarbazepine for the treatment of manic episodes of bipolar disorder.

Bipolar Disorder

Novartis Pharmaceuticals320 participantsStarted Nov 2004

Little Rock, Arkansas, United States • Cerritos, California, United States • San Diego, California, United States +19 more locations

COMPLETEDPhase 359 miles

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

NCT01128894

This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.

Diabetes Mellitus, Type 2

GlaxoSmithKline841 participantsStarted May 2010

Birmingham, Alabama, United States • Chandler, Arizona, United States • Gilbert, Arizona, United States +170 more locations

Find Trials by Condition in Austin

Breast Cancerin Austin Lung Cancerin Austin Prostate Cancerin Austin Colorectal Cancerin Austin Melanomain Austin Leukemiain Austin Lymphomain Austin Pancreatic Cancerin Austin Ovarian Cancerin Austin Brain Cancerin Austin Diabetesin Austin

Data from ClinicalTrials.govTerms

COMPLETEDPhase 274 miles

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

NCT01993641

The purpose of this open label study is to determine whether combining pracinostat (study drug) with Vidaza (azacitidine) or Dacogen (decitabine) will improve clinical responses in Myelodysplastic Syndrome (MDS) patients who have failed an initial single agent hypomethylating agent (HMA), and to provide additional safety and efficacy data.

Myelodysplastic SyndromeMDS

Helsinn Healthcare SA45 participantsStarted Dec 2013

Mobile, Alabama, United States • Duarte, California, United States • Los Angeles, California, United States +18 more locations

COMPLETEDPhase 374 miles

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

NCT01081834

The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.

Diabetes Mellitus, Type 2

Janssen Research & Development, LLC678 participantsStarted Mar 2010

Phoenix, Arizona, United States • Concord, California, United States • Greenbrae, California, United States +75 more locations

COMPLETEDPhase 174 miles

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

NCT02262455

This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.

Ovarian CancerFallopian Tube CancerEndometrial Cancer+1 more

Santa Maria Biotherapeutics32 participantsStarted Oct 2014

Boston, Massachusetts, United States • New York, New York, United States • Nashville, Tennessee, United States +1 more locations

COMPLETEDPhase 280 miles

Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

NCT00057785

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue, prevent or lessen mouth dryness, and may help patients live more comfortably. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of specialized radiation therapy techniques with or without chemotherapy in reducing mouth dryness in patients who have nasopharyngeal cancer.

Head and Neck CancerOral Complications of Radiation TherapyRadiation Toxicity

Radiation Therapy Oncology Group68 participantsStarted Feb 2003

Birmingham, Alabama, United States • Davis, California, United States • Sacramento, California, United States +14 more locations

COMPLETEDPhase 2147 miles

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

NCT01044186

The purpose of this open-label, non-comparative, multi-center protocol was to further evaluate safety and to provide treatment with ICL670 to patients who had or were at risk of life threatening complications due to transfusional iron overload with a documented inability to tolerate any of the commercially available iron chelators due to severe toxicity rendering continued therapy either impossible or hazardous. Patients who were also ineligible for all on-going registration trials with ICL670 were included in the study. In exceptional cases, patients with a degree of iron overload which was not immediately life-threatening and who were ineligible for the registration trials were also enrolled provided they had a well-documented, sound justification for alternative chelation therapy.

Transfusional Iron Overload

Novartis Pharmaceuticals30 participantsStarted Jun 2003

Oakland, California, United States • Orange, California, United States • Boston, Massachusetts, United States +15 more locations

COMPLETED147 miles

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

NCT01819766

This study aims to determine the performance of the Exact IBD-ACRN surveillance test to detect colorectal cancer (CRC) and colorectal neoplasia in patients with inflammatory bowel disease (IBD). Patients with an IBD diagnosis for at least eight years or diagnosis of primary sclerosing cholangitis (PSC) and who are eligible for CRC screening are eligible to participate in this study. Enrolled subjects will collect a stool sample for the Exact IBD-ACRN surveillance test. Subjects must have undergone colonoscopy no more than 90 days prior to enrollment and will undergo colonoscopy or surgical intervention within 120 days of enrollment. Tissue diagnosis of CRC will be established by histopathologic examination.

Inflammatory Bowel Disease (IBD)Primary Sclerosing Cholangitis (PSC)Colorectal Neoplasms+1 more

Exact Sciences Corporation440 participantsStarted Mar 2013

Phoenix, Arizona, United States • La Jolla, California, United States • Miami, Florida, United States +23 more locations

COMPLETEDPhase 3147 miles

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT00003901

RATIONALE: Prognostic testing for early signs of metastases may help doctors detect metastases early and plan more effective treatment. PURPOSE: Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I, stage II, or stage III non-small cell lung cancer that can be removed by surgery.

Alliance for Clinical Trials in Oncology1,310 participantsStarted Jul 1999

Mobile, Alabama, United States • Mobile, Alabama, United States • Los Angeles, California, United States +55 more locations

COMPLETEDPhase 2147 miles

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

NCT01800968

The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical stability at six months as assessed by a composite clinical endpoint.

Acute Heart Failure

Duke University300 participantsStarted Apr 2013

Newark, Delaware, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +22 more locations

COMPLETEDPhase 4182 miles

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

NCT01165684

This trial is conducted in Europe, and North and South America. The aim of this clinical trial is to investigate if the two treatments are equally effective.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S401 participantsStarted Oct 2010

Birmingham, Alabama, United States • Mesa, Arizona, United States • Scottsdale, Arizona, United States +64 more locations

COMPLETEDPhase 3271 miles

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

NCT00488319

The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.

SchizophreniaSchizophrenic DisordersPsychotic Disorders+1 more

Janssen Research & Development, LLC400 participantsStarted Jun 2007

Cerritos, California, United States • San Diego, California, United States • Santa Ana, California, United States +50 more locations

No Longer Available706 miles

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

NCT01120561

This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1 administered by intravenous (IV) infusion.

Metastatic Breast Cancer

Genentech, Inc.Started May 2010

Highland, California, United States • Stockton, California, United States • Denver, Colorado, United States +12 more locations

TERMINATEDPhase 4749 miles

Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

NCT00637780

This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.

Arthritis, Juvenile Rheumatoid

Pfizer2 participantsStarted Jun 2010

Cleveland, Ohio, United States • Guadalajara, Jalisco, Mexico

COMPLETEDPhase 2754 miles

A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients

NCT00358150

Gaucher disease is a genetic disease that results in a deficiency of an enzyme acid beta-glucosidase, also known as glucocerebrosidase. This enzyme is needed to digest a substrate (lipid) called glucosylceramide and, to a lesser degree, glucosylsphingosine. In participants with Gaucher disease, the liver, spleen, bone marrow and brain show increases in lipid concentration, specifically in cells derived from the monocyte/macrophage system. Eliglustat tartrate (Genz-112638) is an oral drug that may regulate the Gaucher disease process by decreasing the synthesis of glucosylceramide. The primary objective of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of eliglustat tartrate, administered as an oral dose of either 50 milligram (mg) twice daily (BID) or 100 mg BID, to men and women with Gaucher disease Type 1 for 52 weeks.

Gaucher Disease, Type 1Cerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency Disease+2 more

Genzyme, a Sanofi Company26 participantsStarted Jun 2006

New York, New York, United States • New York, New York, United States • Buenos Aires, Argentina +14 more locations

COMPLETEDNA923 miles

Remote Access to Care, Everywhere, for Parkinson Disease

NCT02144220

The primary objective of this study is to evaluate the feasibility, efficacy and the value of providing care to individuals with Parkinson disease directly into their homes. The specific aims are: 1. To demonstrate the feasibility of conducting remote evaluations of patients with Parkinson disease nationally; 2. To measure the impact of remote care on each patient's ability to improve his or her quality of life (QoL) and better manage his or her Parkinson disease; and 3. To assess the long-term acceptability to patients in receiving ongoing care remotely via telemedicine.

Parkinson Disease

University of Rochester277 participantsStarted Mar 2014

San Francisco, California, United States • Gainesville, Florida, United States • Rochester, New York, United States

COMPLETEDPhase 1/2926 miles

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

NCT01220271

The purpose of this trial is to show proof of concept that by blocking the Transforming Growth Factor-beta signaling pathway in patients with Glioblastoma, there will be clinical benefit. Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with radiochemotherapy with temozolomide for Phase 2 in patients with glioma eligible to receive radiochemotherapy with temozolomide (e.g. newly diagnosed malignant glioma World Health Organization Grade III and IV). Phase 2a: To confirm the tolerability and evaluate the pharmacodynamic effect of LY2157299 in combination with standard radiochemotherapy in patients with newly diagnosed glioblastoma.

Eli Lilly and Company75 participantsStarted Apr 2011

La Jolla, California, United States • San Francisco, California, United States • Tampa, Florida, United States +7 more locations

COMPLETEDPhase 2977 miles

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

NCT00659789

Current management of HIV infection includes anti-retroviral therapy (ART). ART cannot cure the infection, making it a life-long treatment that requires sustained patient compliance and imposes significant individual and societal financial burdens on healthcare services. Furthermore, ART side effects often require medication that increases the inconveniences and financial burdens of HIV management. Of further concern is the emergence of viruses resistant to ART that can result in treatment failure. ART-free periods could provide substantial benefit. Vacc-4x is a peptide-based HIV immunotherapy that is proposed for prolongation of ART-free periods. The purpose of this study is to determine whether Vacc-4x immunotherapy can give safe ART-free period.

HIV I Infection

Bionor Immuno AS137 participantsStarted Aug 2008

Los Angeles, California, United States • Los Angeles, California, United States • Sacramento, California, United States +15 more locations

COMPLETEDPhase 21368 miles

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT00986414

This phase IIb study is designed to determine the safe and efficacious dose or dose range of AFQ056 for the treatment of patients with moderate to severe Parkinson's disease with L-Dopa induced dyskinesias.

Parkinson DiseaseDyskinesias

Novartis260 participantsStarted Sep 2009

East Gosford, Australia • Heidelberg, Australia • Melbourne, Australia +44 more locations

COMPLETEDPhase 31675 miles

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

NCT01127750

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

Relapsing Multiple Sclerosis

Novartis2,417 participantsStarted May 2010

Box Hill, Australia • Heidelberg, Australia • Kogarah, Australia +286 more locations

PreviousPage 574 of 761Next

Heart Diseasein Austin